Alexion Pharma's most recent trend suggests a bullish bias. One trading opportunity on Alexion Pharma is a Bull Put Spread using a strike $124.00 short put and a strike $115.00 long put offers a potential 39.53% return on risk over the next 31 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $124.00 by expiration. The full premium credit of $2.55 would be kept by the premium seller. The risk of $6.45 would be incurred if the stock dropped below the $115.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Alexion Pharma is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Alexion Pharma is bullish.
The RSI indicator is above 80 which suggests that the stock is in overbought territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Alexion Pharma
Biotech: Steak, But No Sizzle
Fri, 15 Jul 2016 20:19:00 GMT
Why Alexion Pharmaceuticals, Inc. Stock Sank 23.5% in June
Thu, 14 Jul 2016 15:07:00 GMT
Alexion Presents New SBC-103 (rhNAGLU enzyme) Phase 1/2 Data on Brain MRI and Neurocognitive Assessments in Patients with Mucopolysaccharidosis IIIB (MPS IIIB)
Thu, 14 Jul 2016 13:28:06 GMT
noodls – NEW HAVEN, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced today that researchers presented new data from an ongoing open-label, Phase 1/2 trial of intravenous (IV) SBC-103 …
Alexion Presents New SBC-103 (rhNAGLU enzyme) Phase 1/2 Data on Brain MRI and Neurocognitive Assessments in Patients with Mucopolysaccharidosis IIIB (MPS IIIB)
Thu, 14 Jul 2016 13:04:00 GMT
Business Wire – Alexion Pharmaceuticals, Inc. announced today that researchers presented new data from an ongoing open-label, Phase 1/2 trial of intravenous SBC-103 , an investigational enzyme replacement therapy, in children with mucopolysaccharidosis IIIB , a genetic, progressive, and devastating rare lysosomal storage disease.
Amazon Target Primed; Top Banks Initiated Ahead Of Earnings
Wed, 13 Jul 2016 20:02:00 GMT
Related Posts
Also on Market Tamer…
Follow Us on Facebook